Home › Diagnosis and treatment › Lobular breast cancer
Diagnosis & treatment
Lobular breast cancer
Invasive lobular carcinoma starts in the milk-making lobules rather than the ducts, and about one breast cancer in ten is this type. Its cells spread out in single-file lines instead of forming a firm lump, which changes how it is found and measured more than how it is treated.
What lobular breast cancer is
starts in the milk-making lobules rather than the ducts, and about one breast cancer in ten is this type. Its cells have lost the protein that makes cells stick together, so instead of forming a firm lump they spread out in single-file lines through the tissue. That is why lobular cancer is often felt as a thickening rather than a lump, is often hard to see on a mammogram, and often turns out to be larger than the pictures suggested. Most lobular cancers are hormone receptor positive and HER2 negative, and are treated along the hormone receptor positive path, with a few differences.
What is different about lobular breast cancer
- A breast is often added before surgery to measure the true extent, and to check the other breast, since lobular cancer is somewhat more likely to appear in both.
- Because the edges are indistinct, a second operation to clear the after a lumpectomy is somewhat more common.
- Chemotherapy tends to help less than it does for ductal cancers of the same stage, so the endocrine pill carries more of the weight.
- Follow-up pays attention to unusual places, because when lobular cancer does return it can show up in the abdomen or elsewhere rather than in the lung or liver.
Questions to bring to your appointment
These are built for lobular breast cancer. The report decoder narrows the list further from your own report, and the print button there puts it on paper with room to write. Bring someone with you if you can; two sets of ears hear more than one.
Where this comes from
This page is written in plain language from the current NCCN Guidelines for Patients: Invasive Breast Cancer (2026 edition, based on NCCN Guidelines for Breast Cancer version 2.2026), which Dr. Perkins shared as the reference for this page and which is free to read at NCCN.org/patientguidelines, along with NCCN's separate patient guides for DCIS and for metastatic breast cancer. NCCN's material is copyrighted and nothing here reproduces it; readers who want the full detail should go to the source. Breastcancer.org publishes a free guide to reading a pathology report, updated June 2026, at breastcancer.org/pathology-report. Margin definitions follow the Society of Surgical Oncology and American Society for Radiation Oncology consensus statements for invasive cancer (2014) and DCIS (2016). Receptor cutoffs follow the American Society of Clinical Oncology and College of American Pathologists guidelines. Staging follows the American Joint Committee on Cancer, eighth edition. Every clinical statement on this page is listed on the site's verification ledger, and Dr. Perkins read the site on 13 September 2026.
This page is education. It does not diagnose, and the summary it builds is not a treatment plan. Your plan is made with your own care team from your own results.
Published 7 September 2026 as part of the guide; a page of its own since 9 September 2026.